Associated Papers
Malignant adenomyoepithelioma with HRAS G13R mutation: A case report.
Kuwabara H et al.
Oncology Letters, 2026
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and Drugging Pockets.
Hu Z et al.
Jacs Au, 2026
Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.
Hill RD et al.
Biorxiv : the Preprint Server for Biology, 2026
Ras-Related Mutants Identified in Young-Onset Colorectal Cancer Display Divergent Phenotypes and Retain Their Pro-Angiogenic Effects.
David APL et al.
Cells, 2026
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.
Bittner M et al.
International Journal of Molecular Sciences, 2026
Unique hematological presentation of patients with biallelic inactivation of FANCD1/BRCA2.
Niewisch MR et al.
Blood Advances, 2026
Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial.
Slørdahl KS et al.
Acta Oncologica (stockholm, Sweden), 2026
Highly sensitive profiling somatic mutations of thyroid cancer by nucleotide-enrichment-based MALDI-TOF MS assay.
Bai H et al.
Scientific Reports, 2026
The molecular profile of ovarian struma ovarii.
Calejero I et al.
Human Pathology, 2026
Molecular Relationship Between Ovarian Sertoli-Leydig Cell Tumors and Their Heterologous Elements: Emphasis on the Possible Prognostic Significance of TERT Pathogenic Variants.
Trecourt A et al.
The American Journal of Surgical Pathology, 2026
BRAFV600E and NRASQ61R Antibodies Are Sensitive and Specific Diagnostic Biomarkers for BRAF and NRAS Mutations in Conjunctival Melanomas.
Tauziède-Espariat A et al.
The American Journal of Dermatopathology, 2026
Using the Reactome Graph Database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks.
Iengar P et al.
Computational Biology and Chemistry, 2026
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series.
Li JJ et al.
Pathology, 2026
BRAF p.V600E Mutation in Mixed Odontogenic Tumors and Its Clinical Correlation: A Systematic Review and Meta-Analysis.
Chantarangsu S et al.
International Dental Journal, 2026
Insights into RAS-driven melanoma and its therapeutic implications.
Chatziioannou E et al.
Cancer Treatment Reviews, 2026
Next-Generation Sequencing-Based Detection of KRAS G12D Variants in Colorectal Cancer: A Retrospective Cohort Study.
Hekimoglu G et al.
Genes, 2026
Gene mutation in metabolism syndrome with hematologic tumor: A retrospective cohort study.
Zhang Y et al.
Clinical and Experimental Medicine, 2026
Subclinical fields of BRAF V600E-mutant melanocytes populate human skin and are enriched around melanoma and naevi.
Lee KJ et al.
The British Journal of Dermatology, 2026
Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma.
Mao Y et al.
Npj Precision Oncology, 2026
Mutational profiling of HIV+ diffuse large B-cell lymphoma reveals distinct mutational features with evidence of genomic instability.
Roush SM et al.
Aids (london, England), 2026
Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer.
Ochman B et al.
International Journal of Molecular Sciences, 2026
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance.
Kreger BT et al.
Cancer Research, 2026
RAS-GTP Inhibition Overcomes Acquired Resistance to KRASG12C Inhibitors Mediated by Oncogenic and Wild-Type RAS Activation in Non-Small Cell Lung Cancer.
Solanki HS et al.
Cancer Research, 2026
FBXO11 suppression rewires an NPM1-centered interactome influencing the progression of myelodysplastic syndrome.
Niederkorn M et al.
The Journal of Clinical Investigation, 2026
Analytical Validation and Clinical Sensitivity of the Belay Summit™ 2.0 Cerebrospinal Fluid Liquid Biopsy Test-An Expanded Comprehensive Genomic Profiling Platform for Central Nervous System Malignancies.
Khurana S et al.
Cancers, 2026
NF1 Loss Remodels Tumor Niches for Immune Evasion.
Ibrahim M et al.
Biorxiv : the Preprint Server for Biology, 2026
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.
Anastacio Da Costa Carvalho L et al.
Cancer Immunology Research, 2026
PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer.
Wang Y et al.
Military Medical Research, 2026
Genetic Evolution of Melanoma: Comparative Analysis of Candidate Gene Mutations in Healthy Skin, Nevi, and Tumors from the Same Patients.
Gil-Barrachina M et al.
International Journal of Molecular Sciences, 2026
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial.
Rose AAN et al.
Nature Communications, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Upfront menin-inhibitor resistance in multiply pretreated leukemias.
Mahdavi L et al.
Experimental Hematology, 2026
Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.
Khouja M et al.
Leukemia, 2026
Melanomas and Mesenchymal Tumors Arising in Giant Congenital Melanocytic Nevi: Clinico-Pathological and Molecular Characterization of a Case Series.
Rossi S et al.
Pigment Cell & Melanoma Research, 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response.
Wan J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Melanoma of unknown primary: a comprehensive review of immune-mediated pathogenesis and therapies.
Xu W et al.
The Oncologist, 2025
Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma.
Foth M et al.
Biorxiv : the Preprint Server for Biology, 2025
Somatic Mutational Landscape in Follicular Thyroid Cancer: Insights from AACR GENIE Data.
Hsia B et al.
Journal of Personalized Medicine, 2025
O05 Incontinentia pigmenti: clinical heterogeneity and the role of early dermatological recognition.
King Stokes N et al.
The British Journal of Dermatology, 2025
Genetic diversity in melanomagenesis: a comprehensive analysis of BRAF, NRAS, KIT and novel mutations across melanoma subtypes.
Göze ÖF et al.
Bmc Cancer, 2025
Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin (CTNNB1) mutations.
Hewer E et al.
Journal of Clinical Pathology, 2025
Widespread Epistasis between Cancer Driver Mutations and Allele-Specific Copy Number Variations.
Merzliakov S et al.
Biorxiv : the Preprint Server for Biology, 2025
Oral Melanocytic Neoplasms: A Narrative Review.
Maldonado-Mendoza J
Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2025
Molecular profiling and tumour biomarker analysis of GOG281/LOGS: a positive late-phase trial of trametinib for recurrent/persistent low grade-serous ovarian cancer.
Hollis RL et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Age-Related Multigene Analysis of Colorectal Cancer Using Next-Generation Sequencing.
Kozlowska-Geller M et al.
Cancers, 2025